Agios Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AGIO)

$70.33 1.53 (2.22 %)
(As of 01/18/2018 05:09 AM ET)
Previous Close$68.80
Today's Range$69.21 - $71.38
52-Week Range$39.24 - $76.02
Volume410,500 shs
Average Volume682,836 shs
Market Capitalization$3.35 billion
P/E Ratio-11.22
Dividend YieldN/A
Beta1.83

About Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals logoAgios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.

Receive AGIO News and Ratings via Email

Sign-up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AGIO
CUSIPN/A
Phone617-649-8600

Debt

Debt-to-Equity RatioN/A
Current Ratio6.00%
Quick Ratio6.00%

Price-To-Earnings

Trailing P/E Ratio-11.2169059011164
Forward P/E Ratio-10.67
P/E GrowthN/A

Sales & Book Value

Annual Sales$69.89 million
Price / Sales49.06
Cash FlowN/A
Price / CashN/A
Book Value$8.53 per share
Price / Book8.25

Profitability

Trailing EPS($6.27)
Net Income$-198,470,000.00
Net Margins-506.39%
Return on Equity-69.64%
Return on Assets-43.12%

Miscellaneous

Employees287
Outstanding Shares48,750,000

Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals Inc (NASDAQ:AGIO) posted its quarterly earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($1.78) by $0.19. The biopharmaceutical company had revenue of $11.35 million for the quarter, compared to analyst estimates of $10.85 million. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The firm's revenue for the quarter was up 26.4% on a year-over-year basis. During the same quarter last year, the business posted ($1.63) EPS. View Agios Pharmaceuticals' Earnings History.

When will Agios Pharmaceuticals make its next earnings announcement?

Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February, 14th 2018. View Earnings Estimates for Agios Pharmaceuticals.

Where is Agios Pharmaceuticals' stock going? Where will Agios Pharmaceuticals' stock price be in 2018?

11 equities research analysts have issued 12 month price targets for Agios Pharmaceuticals' shares. Their predictions range from $57.00 to $90.00. On average, they expect Agios Pharmaceuticals' share price to reach $75.70 in the next year. View Analyst Ratings for Agios Pharmaceuticals.

What are Wall Street analysts saying about Agios Pharmaceuticals stock?

Here are some recent quotes from research analysts about Agios Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Agios received an FDA approval of Idhifa (enasidenib) in August for treatment of AML, which was a huge boost, given the immense commercial potential in the target market. We are also optimistic about its collaboration with Celgene as it provides Agios with regular funds. The company’s progress with the pipeline candidates, AG-120 and AG-881, has been quite impressive too. In December, the company submitted a new drug application to the FDA for  AG-120 for treatment of AML. Shares of the company have outperformed the industry in the last one year. However, Agios depends heavily on partner Celgene for revenues as Idhifa is only in the early stages of launch. Also, the decision to discontinue the development of AG-519 was disappointing. Stiff competition is another matter of concern for the company." (1/16/2018)
  • 2. Cann analysts commented, "Agios announced on December 5, 2017 the appointment of Jacqualyn Fouse, Ph.D. to its board of directors. Dr. Fouse has served as executive chair of Dermavant since July 2017 and was previously chief operating officer of Celgene and member of Celgene’s board of directors." (12/5/2017)
  • 3. Cowen Inc analysts commented, "Agios ended 2016 with $574MM in cash, enough to last through 2018." (2/16/2017)

Who are some of Agios Pharmaceuticals' key competitors?

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the folowing people:

  • David P. Schenkein M.D., President, Chief Executive Officer, Director (Age 59)
  • Andrew Hirsch, Chief Financial Officer (Age 46)
  • Scott Biller Ph.D., Chief Scientific Officer (Age 61)
  • Christopher Bowden M.D., Chief Medical Officer (Age 56)
  • Steven L. Hoerter, Chief Commercial Officer (Age 46)
  • Jacqualyn A. Fouse Ph.D., Director (Age 56)
  • David Scadden M.D., Director
  • Paul J. Clancy, Independent Director (Age 55)
  • Ian T. Clark, Independent Director (Age 56)
  • Kaye I. Foster-Cheek, Independent Director (Age 57)

Who owns Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Schwab Charles Investment Management Inc. (0.25%) and Bank of Montreal Can (0.01%). Company insiders that own Agios Pharmaceuticals stock include Celgene European Investment Co, David P Schenkein, Lewis Clayton Jr Cantley, Robert Nelsen and Scott Biller. View Institutional Ownership Trends for Agios Pharmaceuticals.

Who bought Agios Pharmaceuticals stock? Who is buying Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc. and Bank of Montreal Can. View Insider Buying and Selling for Agios Pharmaceuticals.

How do I buy Agios Pharmaceuticals stock?

Shares of Agios Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agios Pharmaceuticals' stock price today?

One share of Agios Pharmaceuticals stock can currently be purchased for approximately $70.33.

How big of a company is Agios Pharmaceuticals?

Agios Pharmaceuticals has a market capitalization of $3.35 billion and generates $69.89 million in revenue each year. The biopharmaceutical company earns $-198,470,000.00 in net income (profit) each year or ($6.27) on an earnings per share basis. Agios Pharmaceuticals employs 287 workers across the globe.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]


MarketBeat Community Rating for Agios Pharmaceuticals (AGIO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  239 (Vote Outperform)
Underperform Votes:  236 (Vote Underperform)
Total Votes:  475
MarketBeat's community ratings are surveys of what our community members think about Agios Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Agios Pharmaceuticals (NASDAQ:AGIO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.912.922.922.64
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $75.70$75.70$75.20$62.88
Price Target Upside: 32.41% upside34.99% upside8.53% upside6.24% upside

Agios Pharmaceuticals (NASDAQ:AGIO) Consensus Price Target History

Price Target History for Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ:AGIO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/1/2018OppenheimerSet Price TargetBuy$83.00HighView Rating Details
12/12/2017Canaccord GenuitySet Price TargetBuy$90.00HighView Rating Details
12/5/2017CannReiterated RatingBuyMediumView Rating Details
11/19/2017SunTrust BanksSet Price TargetBuy$80.00N/AView Rating Details
11/2/2017Credit Suisse GroupBoost Price TargetOutperform$61.00 -> $66.00N/AView Rating Details
9/18/2017JPMorgan Chase & Co.Reiterated RatingBuy$76.00LowView Rating Details
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform -> Outperform$78.00HighView Rating Details
8/10/2017Needham & Company LLCBoost Price TargetBuy -> Buy$54.00 -> $72.00MediumView Rating Details
8/2/2017Leerink SwannUpgradeMarket Perform -> Outperform$50.00 -> $80.00HighView Rating Details
8/1/2017Janney Montgomery ScottReiterated RatingHoldHighView Rating Details
2/16/2017CowenReiterated RatingBuyN/AView Rating Details
1/17/2017CIBCUpgradeMarket Perform -> OutperformN/AView Rating Details
8/19/2016BTIG ResearchInitiated CoverageNeutralN/AView Rating Details
8/10/2016Goldman Sachs GroupReiterated RatingNeutral$46.00N/AView Rating Details
(Data available from 1/18/2016 forward)

Earnings

Agios Pharmaceuticals (NASDAQ:AGIO) Earnings History and Estimates Chart

Earnings by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ AGIO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2018($1.65)N/AView Earnings Details
11/1/2017Q3 2017($1.78)($1.59)$10.85 million$11.35 millionViewN/AView Earnings Details
8/8/2017Q2 2017($1.57)($1.78)$10.68 million$11.30 millionViewListenView Earnings Details
5/4/2017Q1 2017($1.80)($1.56)$9.65 million$10.51 millionViewListenView Earnings Details
2/16/2017Q416($1.51)($1.34)$10.89 million$22.65 millionViewListenView Earnings Details
11/3/2016Q316($1.52)($1.63)$7.82 million$8.98 millionViewListenView Earnings Details
8/4/2016Q216($0.48)($1.47)$39.62 million$6.98 millionViewListenView Earnings Details
5/5/2016Q116($0.79)($0.61)$20.94 million$31.30 millionViewListenView Earnings Details
2/18/2016Q415($0.27)($1.08)$28.78 million$6.22 millionViewListenView Earnings Details
11/5/2015Q315($0.89)($1.07)$17.21 million$5.80 millionViewListenView Earnings Details
8/6/2015Q215($0.46)($0.85)$25.75 million$13.20 millionViewListenView Earnings Details
5/7/2015Q115($0.86)($0.13)$10.86 million$34.20 millionViewListenView Earnings Details
2/17/2015Q414($0.55)($0.76)$10.94 million$14.64 millionViewListenView Earnings Details
11/7/2014Q314($0.53)$0.10$8.45 million$33.90 millionViewListenView Earnings Details
8/7/2014Q2($0.47)($0.54)$11.00 million$8.41 millionViewListenView Earnings Details
5/8/2014Q1($0.37)($0.39)$7.19 million$8.41 millionViewListenView Earnings Details
3/6/2014Q4($0.34)($0.40)$6.19 million$6.70 millionViewListenView Earnings Details
11/7/2013($0.28)($0.47)ViewListenView Earnings Details
9/5/2013Q2 2013($0.28)($2.80)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Agios Pharmaceuticals (NASDAQ:AGIO) Earnings Estimates

2018 EPS Consensus Estimate: ($7.22)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($2.06)($2.06)($2.06)
Q2 20181($2.21)($2.21)($2.21)
Q3 20181($2.37)($2.37)($2.37)
Q4 20181($0.58)($0.58)($0.58)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Agios Pharmaceuticals (NASDAQ:AGIO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Agios Pharmaceuticals (NASDAQ AGIO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.43%
Institutional Ownership Percentage: 94.32%
Insider Trades by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)
Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ AGIO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/16/2018David P SchenkeinCEOSell53,000$73.16$3,877,480.0053,000View SEC Filing  
1/10/2018Scott BillerInsiderSell3,000$65.00$195,000.0056,059View SEC Filing  
12/7/2017Lewis Clayton Jr. CantleyDirectorSell3,838$59.37$227,862.0680,851View SEC Filing  
12/1/2017David P SchenkeinCEOSell6,000$61.55$369,300.006,000View SEC Filing  
12/1/2017Scott BillerInsiderSell2,146$60.79$130,455.348,410View SEC Filing  
11/14/2017Lewis Clayton Jr. CantleyDirectorSell4,000$60.88$243,520.0082,394View SEC Filing  
11/1/2017David P SchenkeinCEOSell6,000$63.85$383,100.00View SEC Filing  
11/1/2017Scott BillerInsiderSell2,146$62.69$134,532.74View SEC Filing  
10/17/2017Lewis Clayton Jr. CantleyDirectorSell4,000$71.10$284,400.0084,394View SEC Filing  
10/16/2017Lewis Clayton Jr. CantleyDirectorSell1,000$71.09$71,090.0084,394View SEC Filing  
10/4/2017David P SchenkeinCEOSell80,000$70.14$5,611,200.00View SEC Filing  
10/4/2017Scott BillerInsiderSell10,470$70.00$732,900.00View SEC Filing  
10/2/2017David P SchenkeinCEOSell6,000$66.76$400,560.00View SEC Filing  
10/2/2017Scott BillerInsiderSell2,146$67.23$144,275.58View SEC Filing  
9/18/2017David P SchenkeinCEOSell35,000$67.12$2,349,200.0035,000View SEC Filing  
9/14/2017Lewis Clayton Jr. CantleyDirectorSell4,000$65.59$262,360.0086,394View SEC Filing  
9/13/2017Lewis Clayton Jr. CantleyDirectorSell1,000$65.47$65,470.0086,394View SEC Filing  
9/11/2017Scott BillerInsiderSell15,000$65.00$975,000.006,264View SEC Filing  
9/1/2017David P SchenkeinCEOSell6,000$62.20$373,200.006,000View SEC Filing  
9/1/2017Scott BillerInsiderSell2,146$61.99$133,030.548,410View SEC Filing  
8/23/2017Lewis Clayton Jr. CantleyDirectorSell4,000$56.85$227,400.00View SEC Filing  
8/2/2017David P SchenkeinCEOSell27,000$59.95$1,618,650.003,000View SEC Filing  
8/2/2017Scott BillerInsiderSell23,146$59.60$1,379,501.608,410View SEC Filing  
7/20/2017Lewis Clayton Jr. CantleyDirectorSell9,000$56.36$507,240.0086,697View SEC Filing  
7/19/2017Lewis Clayton Jr. CantleyDirectorSell3,500$56.14$196,490.0086,697View SEC Filing  
7/7/2017Scott BillerInsiderSell2,146$55.00$118,030.008,410View SEC Filing  
7/3/2017David P SchenkeinCEOSell3,000$51.18$153,540.003,000View SEC Filing  
6/21/2017Scott BillerInsiderSell4,292$55.00$236,060.00View SEC Filing  
6/14/2017Lewis Clayton Jr. CantleyDirectorSell2,000$50.87$101,740.0090,197View SEC Filing  
6/7/2017David P SchenkeinCEOSell3,000$50.02$150,060.001,100View SEC Filing  
5/25/2017Lewis Clayton Jr. CantleyDirectorSell2,036$47.10$95,895.6091,206View SEC Filing  
5/1/2017David P SchenkeinCEOSell3,000$50.06$150,180.003,000View SEC Filing  
4/24/2017Celgene European Investment CoMajor ShareholderBuy624,575$49.50$30,916,462.50View SEC Filing  
4/18/2017Lewis Clayton Jr. CantleyDirectorSell5,090$54.37$276,743.3093,751View SEC Filing  
4/17/2017Lewis Clayton Jr. CantleyDirectorSell2,036$55.24$112,468.6493,751View SEC Filing  
4/3/2017David P SchenkeinCEOSell3,000$58.62$175,860.003,000View SEC Filing  
4/3/2017Scott BillerInsiderSell2,146$58.03$124,532.38View SEC Filing  
3/23/2017Lewis Clayton Jr. CantleyDirectorSell2,036$53.11$108,131.9694,769View SEC Filing  
3/20/2017Scott BillerInsiderSell6,438$55.00$354,090.0021,403View SEC Filing  
3/6/2017Robert NelsenDirectorSell40,599$50.84$2,064,053.16109,230View SEC Filing  
2/28/2017Robert NelsenDirectorSell243,082$49.36$11,998,527.52109,230View SEC Filing  
2/23/2017Robert NelsenDirectorSell135,364$49.37$6,682,920.6873,078View SEC Filing  
2/16/2017David P SchenkeinCEOSell6,000$50.01$300,060.006,000View SEC Filing  
10/27/2016Lewis Clayton Jr. CantleyDirectorSell2,504$48.94$122,545.76108,405View SEC Filing  
10/5/2016Scott BillerInsiderSell5,000$55.00$275,000.0048,270View SEC Filing  
9/28/2016Lewis Clayton Jr. CantleyDirectorSell627$54.00$33,858.00109,659View SEC Filing  
9/27/2016Lewis Clayton Jr. CantleyDirectorSell627$54.15$33,952.05109,659View SEC Filing  
9/20/2016Scott BillerInsiderSell5,000$50.00$250,000.0048,270View SEC Filing  
8/30/2016Lewis Clayton Jr. CantleyDirectorSell627$36.81$23,079.87110,913View SEC Filing  
8/29/2016Lewis Clayton Jr. CantleyDirectorSell627$37.81$23,706.87110,913View SEC Filing  
7/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.80$107,171.20112,167View SEC Filing  
7/25/2016Lewis Clayton Jr. CantleyDirectorSell627$41.85$26,239.95112,167View SEC Filing  
6/28/2016Lewis Clayton Jr. CantleyDirectorSell2,504$41.88$104,867.52125,921View SEC Filing  
6/27/2016Lewis Clayton Jr. CantleyDirectorSell627$40.37$25,311.99125,921View SEC Filing  
6/8/2016Scott BillerInsiderSell27,500$65.00$1,787,500.0081,376View SEC Filing  
5/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$51.69$129,431.76127,175View SEC Filing  
4/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$53.44$133,813.76128,429View SEC Filing  
4/25/2016Lewis Clayton Jr. CantleyDirectorSell627$55.00$34,485.00128,429View SEC Filing  
3/30/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.19$93,123.76129,683View SEC Filing  
2/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.90$94,901.60131,086View SEC Filing  
1/29/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.93$107,496.72131,713View SEC Filing  
12/29/2015Lewis Clayton Jr. CantleyDirectorSell10,664$64.93$692,413.52132,967View SEC Filing  
12/15/2015John Duncan HiggonsCOOSell20,000$50.09$1,001,800.0061,835View SEC Filing  
11/17/2015Lewis Clayton Jr. CantleyDirectorSell9,408$59.83$562,880.64138,299View SEC Filing  
11/16/2015John Duncan HiggonsCOOSell20,000$61.51$1,230,200.0081,835View SEC Filing  
11/2/2015Scott BillerinsiderSell5,500$77.12$424,160.0034,070View SEC Filing  
10/23/2015Lewis Clayton Jr. CantleyDirectorSell9,704$61.16$593,496.64143,002View SEC Filing  
10/15/2015John Duncan HiggonsCOOSell20,000$71.04$1,420,800.0081,835View SEC Filing  
9/30/2015Scott BillerinsiderSell5,500$70.44$387,420.0034,070View SEC Filing  
9/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$83.25$807,858.00147,854View SEC Filing  
9/24/2015Glenn GoddardSVPSell6,000$85.97$515,820.00View SEC Filing  
9/15/2015John Duncan HiggonsCOOSell20,000$91.11$1,822,200.00141,835View SEC Filing  
8/18/2015Lewis Clayton Jr. CantleyDirectorSell9,704$94.94$921,297.76View SEC Filing  
8/17/2015John Duncan HiggonsCOOSell20,000$92.24$1,844,800.00131,835View SEC Filing  
7/23/2015Glenn GoddardSVPSell7,000$120.45$843,150.00View SEC Filing  
7/20/2015Scott BillerInsiderSell5,500$113.87$626,285.00View SEC Filing  
7/17/2015Glenn GoddardSVPSell13,000$113.71$1,478,230.00View SEC Filing  
7/16/2015John Duncan HiggonsCOOSell20,000$114.02$2,280,400.00View SEC Filing  
7/16/2015Lewis Clayton Jr. CantleyDirectorSell9,704$114.28$1,108,973.12View SEC Filing  
6/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.13$1,020,181.52View SEC Filing  
6/15/2015John Duncan HiggonsCOOSell7,000$105.23$736,610.00View SEC Filing  
6/8/2015Scott BillerInsiderSell5,500$121.85$670,175.00View SEC Filing  
6/1/2015Christopher BowdenInsiderSell5,000$120.67$603,350.00View SEC Filing  
6/1/2015David P SchenkeinCEOSell13,000$120.67$1,568,710.00View SEC Filing  
5/27/2015David P SchenkeinCEOSell8,929$120.05$1,071,926.45View SEC Filing  
5/27/2015Glenn GoddardSVPSell2,171$120.05$260,628.55View SEC Filing  
5/20/2015Lewis Clayton Jr. CantleyDirectorSell9,704$116.64$1,131,874.56View SEC Filing  
5/15/2015John Duncan HiggonsCOOSell7,417$112.89$837,305.13View SEC Filing  
5/12/2015David P SchenkeinCEOSell5,200$110.02$572,104.00View SEC Filing  
5/8/2015David P SchenkeinCEOSell3,900$101.32$395,148.00View SEC Filing  
5/7/2015Scott BillerInsiderSell5,500$96.32$529,760.00View SEC Filing  
4/24/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.15$1,020,375.60View SEC Filing  
4/15/2015John Duncan HiggonsCOOSell6,583$99.54$655,271.82View SEC Filing  
4/13/2015David P SchenkeinCEOSell3,900$100.03$390,117.00View SEC Filing  
4/8/2015Scott BillerInsiderSell5,500$97.64$537,020.00View SEC Filing  
4/1/2015David P SchenkeinCEOSell3,900$92.54$360,906.00View SEC Filing  
3/27/2015Lewis Clayton Jr. CantleyDirectorSell9,704$93.58$908,100.32View SEC Filing  
3/16/2015Glenn GoddardSVPSell10,000$106.24$1,062,400.00View SEC Filing  
3/16/2015John Duncan HiggonsCOOSell7,000$106.24$743,680.00View SEC Filing  
3/16/2015Scott BillerInsiderSell5,500$106.81$587,455.00View SEC Filing  
3/2/2015David P SchenkeinCEOSell7,800$107.05$834,990.00View SEC Filing  
2/13/2015David P SchenkeinCEOSell1,471$120.22$176,843.62View SEC Filing  
2/13/2015Glenn GoddardSVPSell1,316$120.31$158,327.96View SEC Filing  
2/11/2015Glenn GoddardSVPSell16,513$107.12$1,768,872.56View SEC Filing  
2/9/2015Glenn GoddardSVPSell15,000$105.81$1,587,150.00View SEC Filing  
2/2/2015David P SchenkeinCEOSell10,400$114.31$1,188,824.00View SEC Filing  
1/2/2015David P SchenkeinCEOSell13,000$110.08$1,431,040.00View SEC Filing  
1/2/2015John Duncan HiggonsCOOSell12,000$110.08$1,320,960.00View SEC Filing  
1/2/2015Scott BillerInsiderSell4,500$110.08$495,360.00View SEC Filing  
12/16/2014Celgene European Investment CoMajor ShareholderBuy228,645$110.75$25,322,433.75View SEC Filing  
12/16/2014John MaraganoreDirectorBuy1,806$110.75$200,014.50View SEC Filing  
12/1/2014David P SchenkeinCEOSell13,000$97.03$1,261,390.00View SEC Filing  
12/1/2014John Duncan HiggonsCOOSell12,000$97.03$1,164,360.00View SEC Filing  
12/1/2014Scott BillerInsiderSell4,500$97.03$436,635.00View SEC Filing  
11/3/2014Glenn GoddardSVPSell2,000$81.71$163,420.00View SEC Filing  
11/3/2014John Duncan HiggonsCOOSell13,000$81.71$1,062,230.00View SEC Filing  
11/3/2014Scott BillerInsiderSell4,500$81.71$367,695.00View SEC Filing  
10/1/2014Glenn GoddardSVPSell1,500$60.07$90,105.00View SEC Filing  
10/1/2014John Duncan HiggonsCOOSell13,000$60.07$780,910.00View SEC Filing  
10/1/2014Scott BillerInsiderSell4,500$60.07$270,315.00View SEC Filing  
9/26/2014David P SchenkeinCEOSell60,000$62.68$3,760,800.00View SEC Filing  
9/26/2014Glenn GoddardSVPSell17,500$56.53$989,275.00View SEC Filing  
9/19/2014Scott BillerInsiderSell37,996$50.45$1,916,898.20View SEC Filing  
9/2/2014Glenn GoddardSVPSell10,000$46.30$463,000.00View SEC Filing  
9/2/2014John Duncan HiggonsCOOSell13,000$46.30$601,900.00View SEC Filing  
9/2/2014Scott BillerInsiderSell4,500$46.30$208,350.00View SEC Filing  
8/26/2014John Duncan HiggonsCOOSell5,000$45.05$225,250.00View SEC Filing  
8/11/2014David P SchenkeinCEOSell4,530$40.17$181,970.10View SEC Filing  
7/1/2014David P SchenkeinCEOSell13,000$46.52$604,760.00View SEC Filing  
7/1/2014Glenn GoddardSVPSell3,500$46.52$162,820.00View SEC Filing  
7/1/2014John Duncan HiggonsCOOSell12,000$46.52$558,240.00View SEC Filing  
7/1/2014Scott BillerInsiderSell4,500$46.52$209,340.00View SEC Filing  
6/23/2014John MaraganoreDirectorBuy2,300$43.98$101,154.00View SEC Filing  
6/20/2014Scott BillerInsiderSell2,004$50.05$100,300.20View SEC Filing  
6/13/2014John Duncan HiggonsCOOSell5,000$45.27$226,350.00View SEC Filing  
6/3/2014John Duncan HiggonsCOOSell7,000$34.47$241,290.00View SEC Filing  
5/6/2014John Duncan HiggonsCOOSell5,000$45.73$228,650.00200,090View SEC Filing  
5/1/2014Glenn GoddardSVPSell2,000$42.39$84,780.00View SEC Filing  
5/1/2014John Duncan HiggonsCOOSell7,000$42.39$296,730.00205,090View SEC Filing  
5/1/2014Scott BillerInsiderSell4,500$42.39$190,755.0030,000View SEC Filing  
4/29/2014Celgene European Investment Comajor shareholderBuy294,800$44.00$12,971,200.00View SEC Filing  
4/29/2014John MaraganoreDirectorBuy2,250$44.00$99,000.0046,583View SEC Filing  
4/7/2014Glenn GoddardSVPSell2,000$45.17$90,340.00View SEC Filing  
4/7/2014John Duncan HiggonsCOOSell3,000$45.17$135,510.00209,090View SEC Filing  
4/1/2014Glenn GoddardSVPSell4,000$38.08$152,320.00View SEC Filing  
4/1/2014John Duncan HiggonsCOOSell12,000$38.08$456,960.00209,090View SEC Filing  
4/1/2014Scott BillerInsiderSell4,500$38.08$171,360.0030,000View SEC Filing  
3/7/2014Glenn GoddardSVPSell17,468$42.11$735,577.48View SEC Filing  
3/7/2014John Duncan HiggonsCOOSell14,646$41.41$606,490.86109,090View SEC Filing  
3/3/2014John Duncan HiggonsCOOSell8,000$29.85$238,800.00109,090View SEC Filing  
3/3/2014Scott BillerInsiderSell6,000$29.85$179,100.00View SEC Filing  
2/10/2014Glenn GoddardSVPSell6,000$30.44$182,640.00View SEC Filing  
1/27/2014Glenn GoddardSVPSell7,000$26.29$184,030.00View SEC Filing  
1/21/2014Glenn GoddardSVPSell10,000$34.71$347,100.00View SEC Filing  
7/29/2013Celgene European Investment CoMajor ShareholderBuy708,333$18.00$12,749,994.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Agios Pharmaceuticals (NASDAQ AGIO) News Headlines

Source:
DateHeadline
Agios Pharmaceuticals Inc (AGIO) Expected to Post Earnings of -$1.65 Per ShareAgios Pharmaceuticals Inc (AGIO) Expected to Post Earnings of -$1.65 Per Share
www.americanbankingnews.com - January 17 at 11:36 AM
Agios Pharmaceuticals Inc (AGIO) CEO Sells $3,877,480.00 in StockAgios Pharmaceuticals Inc (AGIO) CEO Sells $3,877,480.00 in Stock
www.americanbankingnews.com - January 16 at 6:36 PM
Zacks Investment Research Lowers Agios Pharmaceuticals (AGIO) to HoldZacks Investment Research Lowers Agios Pharmaceuticals (AGIO) to Hold
www.americanbankingnews.com - January 15 at 5:14 PM
Agios Pharmaceuticals Inc (AGIO) Given Consensus Recommendation of "Buy" by BrokeragesAgios Pharmaceuticals Inc (AGIO) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 15 at 12:06 PM
Agios Pharmaceuticals Sees Unusually Large Options Volume (AGIO)Agios Pharmaceuticals Sees Unusually Large Options Volume (AGIO)
www.americanbankingnews.com - January 14 at 3:40 AM
Scott Biller Sells 3,000 Shares of Agios Pharmaceuticals Inc (AGIO) StockScott Biller Sells 3,000 Shares of Agios Pharmaceuticals Inc (AGIO) Stock
www.americanbankingnews.com - January 12 at 6:58 PM
Stocks Showing Improving Market Leadership: Agios Pharmaceuticals Earns 81 RS RatingStocks Showing Improving Market Leadership: Agios Pharmaceuticals Earns 81 RS Rating
finance.yahoo.com - January 11 at 3:23 PM
Agios Gears Up Pipeline To Create Future Value - Seeking AlphaAgios Gears Up Pipeline To Create Future Value - Seeking Alpha
seekingalpha.com - January 11 at 7:32 AM
Agios Outlines Key 2018 Priorities Expanding Clinical and Research Programs to Drive Long Term Value - GlobeNewswire (press release)Agios Outlines Key 2018 Priorities Expanding Clinical and Research Programs to Drive Long Term Value - GlobeNewswire (press release)
globenewswire.com - January 9 at 8:20 AM
BRIEF-Agios Outlines Key 2018 Priorities Expanding Clinical And Research Programs To Drive Long Term ValueBRIEF-Agios Outlines Key 2018 Priorities Expanding Clinical And Research Programs To Drive Long Term Value
www.reuters.com - January 8 at 11:06 AM
Agios Outlines Key 2018 Priorities Expanding Clinical and Research Programs to Drive Long Term ValueAgios Outlines Key 2018 Priorities Expanding Clinical and Research Programs to Drive Long Term Value
finance.yahoo.com - January 8 at 11:06 AM
Agios to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018Agios to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018
finance.yahoo.com - January 2 at 7:59 AM
Contrasting Agios Pharmaceuticals (AGIO) and The CompetitionContrasting Agios Pharmaceuticals (AGIO) and The Competition
www.americanbankingnews.com - January 1 at 9:10 PM
Zacks: Analysts Anticipate Agios Pharmaceuticals Inc (AGIO) to Announce -$1.65 Earnings Per ShareZacks: Analysts Anticipate Agios Pharmaceuticals Inc (AGIO) to Announce -$1.65 Earnings Per Share
www.americanbankingnews.com - December 31 at 5:28 PM
Head to Head Review: Agios Pharmaceuticals (AGIO) and Its PeersHead to Head Review: Agios Pharmaceuticals (AGIO) and Its Peers
www.americanbankingnews.com - December 31 at 1:28 PM
Comparing Agios Pharmaceuticals (AGIO) & Its CompetitorsComparing Agios Pharmaceuticals (AGIO) & Its Competitors
www.americanbankingnews.com - December 31 at 1:28 PM
Oppenheimer Analysts Give Agios Pharmaceuticals (AGIO) a $83.00 Price TargetOppenheimer Analysts Give Agios Pharmaceuticals (AGIO) a $83.00 Price Target
www.americanbankingnews.com - December 29 at 10:54 PM
ETFs with exposure to Agios Pharmaceuticals, Inc. : December 29, 2017ETFs with exposure to Agios Pharmaceuticals, Inc. : December 29, 2017
finance.yahoo.com - December 29 at 3:22 PM
Celgene (CELG) in Troubled Waters in 17: What Does 2018 Hold?Celgene (CELG) in Troubled Waters in '17: What Does 2018 Hold?
www.msn.com - December 29 at 8:52 AM
Wired News - Agios Pharma Submitted NDA for Ivosidenib for Treatment of Patients with Relapsed/Refractory AML and IDH1 MutationWired News - Agios Pharma Submitted NDA for Ivosidenib for Treatment of Patients with Relapsed/Refractory AML and IDH1 Mutation
finance.yahoo.com - December 28 at 5:03 PM
Financial Analysis: Agios Pharmaceuticals (AGIO) vs. Its RivalsFinancial Analysis: Agios Pharmaceuticals (AGIO) vs. Its Rivals
www.americanbankingnews.com - December 28 at 8:48 AM
Agios Pharmaceuticals (AGIO) Raised to "Sell" at BidaskClubAgios Pharmaceuticals (AGIO) Raised to "Sell" at BidaskClub
www.americanbankingnews.com - December 27 at 9:44 PM
Agios (AGIO) Files NDA for Leukemia Candidate in the US - NasdaqAgios (AGIO) Files NDA for Leukemia Candidate in the US - Nasdaq
www.nasdaq.com - December 27 at 3:12 PM
Agios Submits New Drug Application to the FDA for Ivosidenib for the Treatment of Patients with Relapsed/Refractory ... - GlobeNewswire (press release)Agios Submits New Drug Application to the FDA for Ivosidenib for the Treatment of Patients with Relapsed/Refractory ... - GlobeNewswire (press release)
globenewswire.com - December 27 at 3:12 PM
Agios (AGIO) Files NDA for Leukemia Candidate in the U.S.Agios (AGIO) Files NDA for Leukemia Candidate in the U.S.
finance.yahoo.com - December 27 at 9:59 AM
Agios Pharma (AGIO) Submits NDA to FDA for Ivosidenib for Patients with Relapsed/Refractory AML and an IDH1 ... - StreetInsider.comAgios Pharma (AGIO) Submits NDA to FDA for Ivosidenib for Patients with Relapsed/Refractory AML and an IDH1 ... - StreetInsider.com
www.streetinsider.com - December 26 at 6:22 PM
Agios Pharma (AGIO) Submits NDA to FDA for Ivosidenib for Patients with Relapsed/Refractory AML and an IDH1 MutationAgios Pharma (AGIO) Submits NDA to FDA for Ivosidenib for Patients with Relapsed/Refractory AML and an IDH1 Mutation
www.streetinsider.com - December 26 at 1:05 PM
BRIEF-Agios Submits New Drug Application To The FDA For IvosidenibBRIEF-Agios Submits New Drug Application To The FDA For Ivosidenib
www.reuters.com - December 26 at 1:05 PM
Agios Submits New Drug Application to the FDA for Ivosidenib for the Treatment of Patients with Relapsed/Refractory AML and an IDH1 MutationAgios Submits New Drug Application to the FDA for Ivosidenib for the Treatment of Patients with Relapsed/Refractory AML and an IDH1 Mutation
finance.yahoo.com - December 26 at 1:05 PM
Agios lines up another potential FDA nod with new leukemia drugAgios lines up another potential FDA nod with new leukemia drug
finance.yahoo.com - December 26 at 1:05 PM
Agios Pharmaceuticals (AGIO) and The Competition Head-To-Head AnalysisAgios Pharmaceuticals (AGIO) and The Competition Head-To-Head Analysis
www.americanbankingnews.com - December 22 at 11:32 AM
Analyzing Agios Pharmaceuticals (AGIO) and The CompetitionAnalyzing Agios Pharmaceuticals (AGIO) and The Competition
www.americanbankingnews.com - December 21 at 9:24 PM
Agios Pharmaceuticals Inc (AGIO) Receives Consensus Recommendation of "Buy" from AnalystsAgios Pharmaceuticals Inc (AGIO) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 21 at 11:50 AM
Analyzing Agios Pharmaceuticals (AGIO) & Its CompetitorsAnalyzing Agios Pharmaceuticals (AGIO) & Its Competitors
www.americanbankingnews.com - December 20 at 1:08 AM
Agios Pharmaceuticals (AGIO) Rating Lowered to Strong Sell at BidaskClubAgios Pharmaceuticals (AGIO) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - December 16 at 9:56 AM
 Analysts Expect Agios Pharmaceuticals, Inc. (AGIO) Will Post Quarterly Sales of $16.14 Million Analysts Expect Agios Pharmaceuticals, Inc. (AGIO) Will Post Quarterly Sales of $16.14 Million
www.americanbankingnews.com - December 16 at 7:00 AM
Agios Pharmaceuticals (AGIO) vs. The Competition Head-To-Head ContrastAgios Pharmaceuticals (AGIO) vs. The Competition Head-To-Head Contrast
www.americanbankingnews.com - December 15 at 7:10 PM
Agios Pharmaceuticals is Now Oversold (AGIO) - NasdaqAgios Pharmaceuticals is Now Oversold (AGIO) - Nasdaq
www.nasdaq.com - December 15 at 7:28 AM
Agios Pharmaceuticals: Updates To Thesis And A Look Toward 2018 - Seeking AlphaAgios Pharmaceuticals: Updates To Thesis And A Look Toward 2018 - Seeking Alpha
seekingalpha.com - December 14 at 3:23 PM
Agios Pharmaceuticals (AGIO) Stock Rating Reaffirmed by Canaccord GenuityAgios Pharmaceuticals (AGIO) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - December 12 at 8:38 PM
BRIEF-Agios Pharmaceuticals Presents New Safety Data From Study on Leukemia DrugBRIEF-Agios Pharmaceuticals Presents New Safety Data From Study on Leukemia Drug
www.reuters.com - December 12 at 3:22 PM
New Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial Demonstrate Durable Responses in Patients with IDH1m Relapsed or Refractory AMLNew Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial Demonstrate Durable Responses in Patients with IDH1m Relapsed or Refractory AML
finance.yahoo.com - December 12 at 3:22 PM
Agios Pharmas ivosidenib shows positive effect in early-stage AML study; shares ahead 3% after hours - Seeking AlphaAgios Pharma's ivosidenib shows positive effect in early-stage AML study; shares ahead 3% after hours - Seeking Alpha
seekingalpha.com - December 12 at 7:39 AM
Data from Phase 1 Studies of Ivosidenib or Enasidenib in Combination with Full Doses of Standard of Care Chemotherapy Demonstrate Tolerability and Preliminary Clinical Activity in Newly Diagnosed AML Patients With an IDH MutationData from Phase 1 Studies of Ivosidenib or Enasidenib in Combination with Full Doses of Standard of Care Chemotherapy Demonstrate Tolerability and Preliminary Clinical Activity in Newly Diagnosed AML Patients With an IDH Mutation
finance.yahoo.com - December 12 at 7:39 AM
Agios targeting cancer medicinesAgios targeting cancer medicines
finance.yahoo.com - December 12 at 7:39 AM
Agios Pharmaceuticals (AGIO) Buy Rating Reiterated at OppenheimerAgios Pharmaceuticals' (AGIO) Buy Rating Reiterated at Oppenheimer
www.americanbankingnews.com - December 11 at 5:08 PM
Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically ... - GlobeNewswire (press release)Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically ... - GlobeNewswire (press release)
globenewswire.com - December 11 at 7:22 AM
Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase DeficiencyAgios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase Deficiency
finance.yahoo.com - December 11 at 7:22 AM
Cambridge biotechs among big winners at ASH blood disease conferenceCambridge biotechs among big winners at ASH blood disease conference
finance.yahoo.com - December 11 at 7:22 AM
Agios Pharmaceuticals, Inc. (AGIO) Director Sells $227,862.06 in StockAgios Pharmaceuticals, Inc. (AGIO) Director Sells $227,862.06 in Stock
www.americanbankingnews.com - December 8 at 5:50 PM

SEC Filings

Agios Pharmaceuticals (NASDAQ:AGIO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Agios Pharmaceuticals (NASDAQ:AGIO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Agios Pharmaceuticals (NASDAQ AGIO) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.